Minerva Neurosciences | NERV - 资产





资产 更改 日
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Adma Biologics USD 665.18M 40.94M 2026-03
ALKERMES USD 4.39B 135.05M 2026-06
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
AstraZeneca USD 115.83B 1.82B 2026-06
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 145.86M 10.71M 2026-03
CSL USD 37.9B 1.5B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
J&J USD 201.06B 167M 2026-06
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Novartis USD 122.03B 3.5B 2026-06
Novavax USD 1.04B 133.35M 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Takeda JPY 15.66T 210.16B 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12